22 May 2013
Keywords: chr-2797, enters, ph, ii, trial, aml, oxford
Article | 02 April 2007
Oxford, UK-based Chroma Therapeutics says that its oral, once-daily experimental cancer therapy CHR-2797 has entered its first Phase II
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 April 2007
21 May 2013
© 2013 thepharmaletter.com